Aspira Pathlab & Diagnostics Ltd
BSE:540788
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aspira Pathlab & Diagnostics Ltd
Total Liabilities & Equity
Aspira Pathlab & Diagnostics Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aspira Pathlab & Diagnostics Ltd
BSE:540788
|
Total Liabilities & Equity
₹201.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Medinova Diagnostic Services Ltd
BSE:526301
|
Total Liabilities & Equity
₹69.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Total Liabilities & Equity
₹29.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Total Liabilities & Equity
₹19.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Aspira Pathlab & Diagnostics Ltd
Glance View
Aspira Pathlab & Diagnostics Ltd. engages in the operation of diagnostic centers and laboratories. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-12-05. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The firm carries out pathological investigations in various branches, including bio-chemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations. The firm's tests include COVID-19 tests, health packages and pathology tests. Its COVID-19 tests include Shanti Screening Test, COVID-19 Antibody Test, COVID-19 Surveillance Profile, COVID-19 RT-PCR Test, COVID-19 Detection Profile 1 and others.
See Also
What is Aspira Pathlab & Diagnostics Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
201.6m
INR
Based on the financial report for Dec 31, 2025, Aspira Pathlab & Diagnostics Ltd's Total Liabilities & Equity amounts to 201.6m INR.
What is Aspira Pathlab & Diagnostics Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
6%
Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for Aspira Pathlab & Diagnostics Ltd have been 5% over the past three years , 6% over the past five years .
